Avalo Therapeutics (AVTX) Director Michael Heffernan Receives Award

What Happened Michael Thomas Heffernan, a director of Avalo Therapeutics, was granted a derivative equity award on 2026-06-02 covering 29,500 shares. The grant is reported at $0.00 per share in the Form 4 and is described in the filing as a stock option that vests 100% on the first anniversary of the grant, subject to continued service. This was an award/grant (acquisition), not a sale or exercise.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-04.
• Transaction type: Award/Grant (derivative stock option) for 29,500 shares; reported price $0.00.
• Vesting: 100% vests on the first anniversary of the grant, contingent on continued service (footnote F1).
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Filing was submitted two days after the grant date (appears timely under standard Form 4 reporting rules).

Context This was a director equity grant (option), not an exercise or sale — no immediate cash or shares changed hands. Director grants like this are common as compensation and do not by themselves indicate a buy/sell signal; the award becomes economically meaningful only as it vests and if/when options are exercised or shares are sold.